研究结论和讨论部分指出，本研究构建的基于 ADME 基因的风险评估模型对膀胱癌预后具有较高的预测准确性，为膀胱癌的个性化治疗提供了重要参考。功能富集分析揭示了高、低风险组患者独特的免疫相关特征，将 ADME 基因表达模式与肿瘤微环境的复杂动态联系起来。此外，研究还确定了 CYP2C8 ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and ...

Keep reading to learn how nasal sumatriptan works, who could benefit, and how it compares with other types of sumatriptan.

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET) and ...